Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor ConferenceGlobeNewsWire • 09/20/23
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/29/23
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundZacks Investment Research • 08/22/23
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023GlobeNewsWire • 08/03/23
Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trialProactive Investors • 07/31/23
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBrGlobeNewsWire • 07/31/23
Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSKSeeking Alpha • 07/05/23
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive OfficerGlobeNewsWire • 06/14/23
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/23
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business UpdateGlobeNewsWire • 05/11/23
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023GlobeNewsWire • 05/04/23
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The MarketSeeking Alpha • 04/21/23
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious DiseasesGlobeNewsWire • 04/14/23
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 03/30/23
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023GlobeNewsWire • 03/13/23
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023GlobeNewsWire • 03/06/23
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundZacks Investment Research • 02/23/23
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/22/23
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22